The Directorate of Revenue Intelligence conducted searches at Cipla's office in Vikhroli, Mumbai, and its depot in Bhiwandi, Thane. The action pertains to the classification and exemption of an imported pharmaceutical finished product.

Pharmaceutical major Cipla has informed stock exchanges that the Directorate of Revenue Intelligence (DRI), Mumbai zonal unit, conducted searches at two of its facilities. The official search operations took place on Monday.

According to the company's disclosure to the stock exchange, the inquiry is specifically related to the classification and exemption of an imported pharmaceutical finished product.

Addressing potential concerns regarding business continuity and financial health, Cipla stated that there is no material impact on the company's financials, operations, or other activities as a result of the search.

The search covered Cipla's corporate office located in Vikhroli, Mumbai, alongside its storage depot situated in Bhiwandi, Thane. The company has not provided further details regarding the specific imported product under review, nor has the DRI released a separate public statement regarding the operation.

Cipla remains compliant with regulatory disclosure norms and has communicated the relevant facts to the exchanges as required for publicly listed entities.

"Regulatory inquiries and classification reviews involving imported products are standard administrative processes for large pharmaceutical companies operating in global supply chains. For publicly listed entities, timely disclosure to stock exchanges is crucial to maintain investor transparency and prevent speculation. Cipla's official statement indicating no material impact on its financials or operations should reassure stakeholders while the authorities complete their review of the imported pharmaceutical product in question." — Dr. Shishir Gupta, Founder & CEO, StartupLanes

Recent StartupLanes Articles

Browse through our 30 latest publications on venture capital, startups, and angel investing.